PDF(Pubmed)
Abstract：
Worldwide, diabetes and its complications have seriously affected people\'s quality of life and become a serious public health problem. C-peptide is not only an indicator of pancreatic β-cell function, but also a biologically active peptide that can bind to cell membrane surface signaling molecules and activate downstream signaling pathways to play antioxidant, anti-apoptotic and inflammatory roles, or regulate cellular transcription through internalization. It is complex how C-peptide is related to diabetic complications. Both deficiencies and overproduction can lead to complications, but their mechanisms of action may be different. C-peptide replacement therapy has shown beneficial effects on diabetic complications in animal models when C-peptide is deficient, but results from clinical trials have been unsatisfactory. The complex pattern of the relationship between C-peptide and diabetic chronic complications has not yet been fully understood. Future basic and clinical studies of C-peptide replacement therapies will need to focus on baseline levels of C-peptide in addition to more attention also needs to be paid to post-treatment C-peptide levels to explore the optimal range of fasting C-peptide and postprandial C-peptide maintenance.
摘要：
全球,糖尿病及其并发症已严重影响人们的生活质量,成为严重的公共卫生问题。C肽不仅是胰岛β细胞功能的指标,而且是一种生物活性肽，可以与细胞膜表面信号分子结合并激活下游信号通路发挥抗氧化作用，抗凋亡和炎症作用，或通过内化调节细胞转录。C肽与糖尿病并发症的关系很复杂。不足和生产过剩都会导致并发症，但是它们的作用机制可能不同。当C肽缺乏时，C肽替代疗法对动物模型中的糖尿病并发症显示出有益的作用。但是临床试验的结果并不令人满意。C肽与糖尿病慢性并发症之间关系的复杂模式尚未完全了解。未来的C肽替代疗法的基础和临床研究将需要关注C肽的基线水平，除了更多的关注还需要支付治疗后的C肽水平，以探索空腹C的最佳范围肽和餐后C肽维持。
